Alzamend Neuro Inc
ALZNAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Ascendiant Capital | maintain | Buy | Aug 19, 2026 |
| Ascendiant Capital | maintain | Buy | Dec 22, 2025 |
| Ascendiant Capital | maintain | Buy | Sep 25, 2025 |
| Ascendiant Capital | maintain | Buy | Aug 21, 2025 |
| Ascendiant Capital | maintain | Buy | Mar 17, 2025 |
| Ascendiant Capital | maintain | Buy | Dec 16, 2024 |
| Ascendiant Capital | maintain | Buy | Nov 11, 2024 |
| Maxim Group | maintain | Buy | Apr 12, 2023 |
| Ascendiant Capital | maintain | Buy | Oct 1, 2021 |
Earnings History
Next report: Dec 8, 2026 · EPS est. $-0.23| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Sep 10, 2026 | $-0.68 | $-0.56 | — | — |
| Jul 22, 2026 | $-0.74 | $-0.67 | — | — |
| Mar 11, 2026 | $-0.58 | $-0.53 | — | — |
| Dec 9, 2025 | $-0.30 | $-0.83 | — | — |
| Sep 10, 2025 | $-1.28 | $-3.69 | — | — |
| Jul 29, 2025 | $-2.36 | $-2.70 | — | — |
| Mar 10, 2025 | $-1.71 | $-2.61 | — | — |
| Dec 11, 2024 | $-3.60 | $-21.42 | — | — |
News
Alzamend Neuro (ALZN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Neuroscience 2026, the annual meeting of the Society for Neuroscience, will be held November 14–18, 2026 in Washington, DC Presentation Title: Assessing Treatment-Associated Brain Network Changes Following a Novel Lithium Treatment Using 7T Resting-State fMRI – Results from a Randomized Phase 1/2A Clinical Trial ATLANTA, Aug. 20, 2026 /PRNewswire/ -- Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatm…
ISMRM Workshop on Beyond Protons: Challenges and Advances in X-Nuclei MR will be held September 28 – October 1, 2026 at the Universitat Oberta de Catalunya (UOC) in Barcelona, Spain Presentation will report first-of-its-kind pharmacokinetic imaging results from Phase 1/2A trial of AL001, Alzamend's novel organic lithium drug candidate, in healthy human subjects ATLANTA, Aug. 18, 2026 /PRNewswire/ -- Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company f…